Roche Holding AG (OTCMKTS:RHHBY) Stock Holdings Reduced by Saratoga Research & Investment Management

Saratoga Research & Investment Management reduced its stake in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 6.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,174,306 shares of the company's stock after selling 151,504 shares during the period. Roche makes up approximately 3.8% of Saratoga Research & Investment Management's portfolio, making the stock its 10th biggest position. Saratoga Research & Investment Management's holdings in Roche were worth $75,840,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Bard Financial Services Inc. grew its stake in shares of Roche by 37.7% in the fourth quarter. Bard Financial Services Inc. now owns 110,850 shares of the company's stock valued at $3,866,000 after buying an additional 30,350 shares in the last quarter. Altrius Capital Management Inc boosted its holdings in Roche by 0.3% during the 4th quarter. Altrius Capital Management Inc now owns 183,448 shares of the company's stock valued at $6,399,000 after acquiring an additional 603 shares during the period. SVB Wealth LLC acquired a new position in Roche in the 4th quarter valued at about $555,000. Diversified Trust Co increased its stake in Roche by 1.2% during the fourth quarter. Diversified Trust Co now owns 60,453 shares of the company's stock worth $2,130,000 after purchasing an additional 711 shares during the period. Finally, Verity Asset Management Inc. lifted its position in shares of Roche by 26.8% during the fourth quarter. Verity Asset Management Inc. now owns 8,036 shares of the company's stock worth $280,000 after purchasing an additional 1,697 shares in the last quarter.

Wall Street Analyst Weigh In

RHHBY has been the topic of several recent research reports. UBS Group raised shares of Roche from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Sanford C. Bernstein raised Roche to a "strong-buy" rating in a research report on Thursday, January 30th. Finally, Morgan Stanley initiated coverage on Roche in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy".

Roche Stock Down 5.9 %

OTCMKTS RHHBY traded down $2.37 on Friday, hitting $37.65. 3,869,835 shares of the stock were exchanged, compared to its average volume of 3,245,635. Roche Holding AG has a fifty-two week low of $29.20 and a fifty-two week high of $44.31. The company has a 50-day moving average price of $41.40 and a 200-day moving average price of $38.72. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.